Clinically, all patients with interstitial lung disease(ILD) were observed, and relevant clinical data were collected. Bronchoscopic specimens were collected according to the condition of the enrolled patients, and the rapid on site evaluation(ROSE) was evaluated, combined with the metagenomic next generation sequencing(mNGS) results of these patients. To observe the etiology and biological characteristics of exacerbation in patients with interstitial lung disease.

All patients undergo polysomnography (PSG) and drug-induced sleep endoscopy(DISE). The biological specimens was obtained for molecular biology or other tests.We detected ZNF331, Claudin1, Claudin2, Claudin3, Claudin4, and IL22 as biomarkers to differentiate the diagnostic efficiency of OSA in ILD, ILD+OSA, OSA, and Ctrl groups, respectively

Inclusion criteria:

• over 18 years old and under 80 years old.
• Clinical diagnosis of interstitial lung disease or obstructive respiratory sleep apnea syndrome.
• Patient is conscious and capable of signing informed consent.
• The patient may wear a polysomnograph.

Exclusion criteria:

• malignant tumors.
• severe heart failure.
• uremia.
• autoimmune diseases.
• pulmonary embolism, and end-stage chronic obstructive pulmonary disease.
• Patients with mental illnesscannot sign informed consent on their own.

Interstitial lung disease and respiratory sleep apnoea